Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocytosis 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 14fludarabine phosphate 13ruxolitinib 9Busulfan 9Antilymphocyte Serum 9fludarabine 8Peripheral Blood Stem Cell Transplantation 8Filgrastim 8Whole-Body Irradiation 7Cyclosporine 7Tacrolimus 6Radiotherapy 6Mycophenolic Acid 6Methylprednisolone 6Methotrexate 5Melphalan 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Azacitidine 5Imatinib Mesylate 4Alemtuzumab 4ponatinib 3parsaclisib 3fedratinib 3Stem Cell Transplantation 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Decitabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myeloproliferative Disorders × luspatercept × Clear all
NCT05005182 2024-09-19

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Mayo Clinic

Phase 2 Terminated
3 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡